Skip to main content

Table 2 Clinical significance of MIR22HG in various human tumors

From: Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers

Cancer type Clinicopathological features References
thyroid carcinoma Low MIR22HG expression was related to tumor size (P = 0.015), TNM stage (P = 0.022) and poor overall survival (P = 0.030). [21]
Low MIR22HG expression was significantly related to the lymph node metastasis status (P < 0.01), the residual tumor status (P < 0.05), N stage (P < 0.05), tumor grade (P < 0.001) and T stage (P < 0.001) while high MIR22HG expression was significantly correlated with the disease recurrence rate (P < 0.01), overall survival time (P = 0.0665) and disease-free survival time (P < 0.05) in TC by analyzing TCGA, the GSE29265, GSE33630, and GSE55091 public datasets. [22]
hepatocellular carcinoma Low MIR22HG expression was associated with short overall survival (P = 0.045) and poor disease-free survival (P = 0.036). [23]
Patients with high MIR22HG expression exhibited better overall survival (145-patient cohort: P = 0.001; TCGA cohort: P = 0.015) and disease-free survival (145-patient cohort: P = 0.042; TCGA cohort: P = 0.003) than those with low MIR22HG expression. [24]
cholangiocarcinoma Low MIR22HG expression was positively correlated with advanced clinical stage (TNM) (P = 0.039), large tumor size (P = 0.002), lymph node metastasis (P = 0.0001), and poor overall survival (P = 0.020). [26]
colorectal
cancer
Low MIR22HG expression was significantly associated
with poor overall survival (P = 0.0008) and disease-free survival (P = 0.0009).
[27]
gastric cancer Low MIR22HG expression indicated a low 5-year overall survival rate (P < 0.05). [28]
non-small cell lung cancer Low MIR22HG expression was correlated with poor patient survival (P = 0.003) in an independent UM cohort including 101 LUAD tissues and 27 normal lung tissues. [30]
glioblastoma High MIR22HG expression was associated with patient age (P < 0.001), Karnofsky Performance Status score (P < 0.001), advanced tumor grade and poor overall survival (P < 0.05). [31]